Q BioMed Inc.

Equities

QBIO

US74736N1054

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:32:26 2024-04-18 pm EDT			5-day change	1st Jan Change
0.0002 ^USD	+100.00%		0.00%	-50.00%

2023	Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	CI
2023	Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	CI

Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2022

April 14, 2022 at 05:01 pm EDT

Q BioMed Inc. reported earnings results for the first quarter ended February 28, 2022. For the first quarter, the company reported sales was USD 0.075059 million. Net loss was USD 2.29 million compared to USD 2.48 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.11 a year ago.

Latest news about Q BioMed Inc.

Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-06-16	CI
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	23-05-26	CI
Q BioMed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent from United States Patent Office	23-02-10	CI
Q BioMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-11-03	CI
Q BioMed Inc. Announces Issuance of Patent for Groundbreaking Gdf15 Biomarker	22-09-27	CI
Q BioMed Inc. Reports Second Quarter Revenues in 2022	22-07-29	CI
Q BioMed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	22-07-28	CI
Q BioMed Inc. Announces Publication of Pre-Clinical Research Showing Superior Safety and Efficacy Against Current First Line Therapy of Its Drug Candidate Uttroside-B for Liver Cancer	22-07-26	CI
Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2022	22-04-14	CI
Q BioMed Inc. Announces Publication of Research Showing Augmented Efficacy of its Drug Candidate Uttroside-B Against Liver Cancer	22-03-16	CI
Q BioMed Inc. Announces Initial $500,000 Order of Strontium89 to Chinese Market	22-03-07	CI
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2021	22-02-28	CI
Q BioMed Inc. Auditor Raises 'Going Concern' Doubt	22-02-27	CI
Q BioMed Inc. Bolsters Commercialization of Strontium89 with EVERSANA Partnership	21-11-08	CI
Q Biomed Inc. Reports Earnings Results for the Third Quarter Ended August 31, 2021	21-10-15	CI
Q BioMed Inc. announced that it has received $2.015 million in funding from GS Capital Partners LLC	21-10-04	CI
Q BioMed Inc. announced that it expects to receive $2.015 million in funding from GS Capital Partners LLC	21-09-28	CI
Q Biomed Inc. Updates on Covid-19 Therapeutic Development and Clinical Trials - Man-19 Therapeutic Program Heading to Clinical Trial in Early 2022	21-09-22	CI
Q Biomed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent in South Korea and Shows Positive Results in Initial Pre-Clinical Testing	21-08-24	CI
Q BioMed Inc. Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada	21-08-10	CI
Q BioMed Inc. announced that it has received $0.75 million in funding from Platinum Point Capital LLC	21-07-25	CI
Q Biomed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East	21-07-12	CI
Q BioMed Inc. announced that it expects to receive $20 million in funding from Aedesius Holdings Ltd	21-05-04	CI
Q Biomed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2021	21-04-14	CI
Q Biomed Awards Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs	21-03-02	CI

Chart Q BioMed Inc.

Duration

Period

More charts

Company Profile

Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Companyâs pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. QBM-001 is designed to alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disabilities caused from being non-verbal. Uttroside-B is a potential chemotherapeutic for liver cancer. Its primary indication, MAN-01, is for the treatment of primary open angle glaucoma, wherein it is developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of glaucoma.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
Q BIOMED INC.	-50.00%	29.02K
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs